Literature DB >> 11606431

Signaling and antiproliferative effects mediated by GnRH receptors after expression in breast cancer cells using recombinant adenovirus.

H M Everest1, J N Hislop, T Harding, J B Uney, A Flynn, R P Millar, C A McArdle.   

Abstract

GnRH receptors (GnRH-Rs) are found in human cancers, including those of the breast, and GnRH can inhibit the growth of cell lines derived from such cancers. Although pituitary and extrapituitary GnRH-R transcripts appear identical, their functional characteristics may differ. Most extrapituitary GnRH-Rs have low affinity for GnRH analogs and may not activate PLC or discriminate between agonists and antagonists in the same way as pituitary GnRH-Rs. Here we have assessed whether GnRH-Rs expressed exogenously in breast cancer cells differ from those in gonadotropes. We found no evidence for endogenous GnRH-Rs in MCF7 cells, but after infection with adenovirus expressing the GnRH-R (Ad GnRH-R) at a multiplicity of infection of 10 or greater, at least 80% expressed GnRH-Rs. These had high affinity (K(d) for [(125)I]buserelin, 1.4 nM) and specificity (rank order of potency, buserelin>GnRH>>chicken GnRH-II) and mediated stimulation of [(3)H]IP accumulation. Increasing viral titer [from multiplicity of infection, 3-300] increased receptor number (10,000-225,000 sites/cell) and [(3)H]IP responses. GnRH stimulated ERK2 phosphorylation in Ad GnRH-R-infected cells, and this effect, like stimulation of [(3)H]IP accumulation, was blocked by GnRH-R antagonists. GnRH also inhibited [(3)H]thymidine incorporation into Ad GnRH-R-infected cells (but not control cells). This effect was mimicked by agonist analogs and inhibited by two antagonists. Thus, when exogenous GnRH-Rs are expressed at density comparable to that in gonadotropes, they are functionally indistinguishable from the endogenous GnRH-Rs in gonadotropes, and increasing expression of high affinity GnRH-Rs can dramatically enhance the direct antiproliferative effect of GnRH agonists on breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11606431     DOI: 10.1210/endo.142.11.8503

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  11 in total

1.  Establishment of an mKate2-Expressing Cell Line for Non-Invasive Real-Time Breast Cancer In Vivo Imaging.

Authors:  Ivan Vuletic; Jinghao Liu; Honglian Wu; Yichen Ding; Yu Lei; Changhui Li; Desheng Zhu; Qiushi Ren; Hongfang Sun; Jun Li
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

2.  Gonadotropin-releasing hormone analog structural determinants of selectivity for inhibition of cell growth: support for the concept of ligand-induced selective signaling.

Authors:  Rakel López de Maturana; Adam J Pawson; Zhi-Liang Lu; Lindsay Davidson; Stuart Maudsley; Kevin Morgan; Simon P Langdon; Robert P Millar
Journal:  Mol Endocrinol       Date:  2008-05-08

3.  NAV3, a Tumor Suppressor Gene, Is Decreased in Uterine Leiomyoma Tissue and Cells.

Authors:  Jasmine M Aly; Terrence D Lewis; Toral Parikh; Joy Britten; Minnie Malik; William H Catherino
Journal:  Reprod Sci       Date:  2020-01-01       Impact factor: 3.060

4.  GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines.

Authors:  Kevin Morgan; Colette Meyer; Nicola Miller; Andrew H Sims; Ilgin Cagnan; Dana Faratian; David J Harrison; Robert P Millar; Simon P Langdon
Journal:  BMC Cancer       Date:  2011-11-03       Impact factor: 4.430

5.  Gonadotropin‑releasing hormone inhibits the proliferation and motility of nasopharyngeal carcinoma cells.

Authors:  Loong Hung Teng; Munirah Ahmad; Wayne Tiong Weng Ng; Subathra Sabaratnam; Maria Ithaya Rasan; Ishwar Parhar; Alan Soo Beng Khoo
Journal:  Mol Med Rep       Date:  2015-07-03       Impact factor: 2.952

Review 6.  Applying Multivariate Adaptive Splines to Identify Genes With Expressions Varying After Diagnosis in Microarray Experiments.

Authors:  Fenghai Duan; Ye Xu
Journal:  Cancer Inform       Date:  2017-05-04

Review 7.  Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs.

Authors:  Maira Huerta-Reyes; Guadalupe Maya-Núñez; Marco Allán Pérez-Solis; Eunice López-Muñoz; Nancy Guillén; Jean-Christophe Olivo-Marin; Arturo Aguilar-Rojas
Journal:  Front Oncol       Date:  2019-10-01       Impact factor: 6.244

8.  Gonadotropin-releasing hormone receptor activates GTPase RhoA and inhibits cell invasion in the breast cancer cell line MDA-MB-231.

Authors:  Arturo Aguilar-Rojas; Maira Huerta-Reyes; Guadalupe Maya-Núñez; Fabián Arechavaleta-Velásco; P Michael Conn; Alfredo Ulloa-Aguirre; Jesús Valdés
Journal:  BMC Cancer       Date:  2012-11-23       Impact factor: 4.430

9.  Plasma membrane expression of GnRH receptors: regulation by antagonists in breast, prostate, and gonadotrope cell lines.

Authors:  Ann R Finch; Kathleen R Sedgley; Christopher J Caunt; Craig A McArdle
Journal:  J Endocrinol       Date:  2008-02       Impact factor: 4.286

10.  Gonadotropin releasing hormone analogue (GnRHa) alters the expression and activation of Smad in human endometrial epithelial and stromal cells.

Authors:  Xiaoping Luo; Jingxia Xu; Nasser Chegini
Journal:  Reprod Biol Endocrinol       Date:  2003-12-16       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.